Abstract
The TNFα receptor super-family consists of several members sharing a sequence homology in a unique function domain, the death domain, which is located in the intracellular portion of the receptor. These so-called death receptors, including Fas, TNF-R1 and TRAIL-R1 / TRAIL-R2, are expressed on hepatocytes. When stimulated by their ligands, FasL, TNFα or TRAIL, respectively, the death receptors can activate multiple death domain-initiated apoptosis programs, including both extrinsic and intrinsic pathways. A cascade of caspases is activated, which cleave proteins important for the cell structure and function. Activation of the intrinsic pathway also leads to mitochondrial release of several apoptotic proteins and mitochondrial dysfunction, which kill the cell through both caspase-dependent and caspase-independent mechanisms. Death receptor-induced hepatocyte apoptosis contributes to the development of a number of liver diseases, including viral hepatitis, inflammatory hepatitis, Wilsons disease, alcoholic liver disease, endotoxiemia-induced liver failure and ischemia / reperfusion-induced liver damage. This article comprehensively reviews the mechanisms of induction and regulation of death receptor-initiated apoptosis in hepatocytes, examines how these molecular events affect our understanding of the pathogenesis of these diseases and further discusses the potential therapeutic application of the knowledge. We hope we can provide a cohesive and integrated perspective on the many aspects of these complicated processes.
Keywords: death receptor, hepatocyte apoptosis, liver injury, fas, inflammatory hepatitis
Current Molecular Medicine
Title: Death Receptor Activation-Induced Hepatocyte Apoptosis and Liver Injury
Volume: 3 Issue: 6
Author(s): Xiao-Ming Yin and Wen-Xing Ding
Affiliation:
Keywords: death receptor, hepatocyte apoptosis, liver injury, fas, inflammatory hepatitis
Abstract: The TNFα receptor super-family consists of several members sharing a sequence homology in a unique function domain, the death domain, which is located in the intracellular portion of the receptor. These so-called death receptors, including Fas, TNF-R1 and TRAIL-R1 / TRAIL-R2, are expressed on hepatocytes. When stimulated by their ligands, FasL, TNFα or TRAIL, respectively, the death receptors can activate multiple death domain-initiated apoptosis programs, including both extrinsic and intrinsic pathways. A cascade of caspases is activated, which cleave proteins important for the cell structure and function. Activation of the intrinsic pathway also leads to mitochondrial release of several apoptotic proteins and mitochondrial dysfunction, which kill the cell through both caspase-dependent and caspase-independent mechanisms. Death receptor-induced hepatocyte apoptosis contributes to the development of a number of liver diseases, including viral hepatitis, inflammatory hepatitis, Wilsons disease, alcoholic liver disease, endotoxiemia-induced liver failure and ischemia / reperfusion-induced liver damage. This article comprehensively reviews the mechanisms of induction and regulation of death receptor-initiated apoptosis in hepatocytes, examines how these molecular events affect our understanding of the pathogenesis of these diseases and further discusses the potential therapeutic application of the knowledge. We hope we can provide a cohesive and integrated perspective on the many aspects of these complicated processes.
Export Options
About this article
Cite this article as:
Yin Xiao-Ming and Ding Wen-Xing, Death Receptor Activation-Induced Hepatocyte Apoptosis and Liver Injury, Current Molecular Medicine 2003; 3 (6) . https://dx.doi.org/10.2174/1566524033479555
DOI https://dx.doi.org/10.2174/1566524033479555 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
Call for Papers in Thematic Issues
Molecular and Cellular Mechanisms in Vertigo / Vestibular Disorders
Vertigo and vestibular diseases are common among middle-aged and older adults, significantly increasing the risk of falls and leading to injuries and disabilities. Despite their prevalence, therapeutic advancements are hindered by a limited understanding of the underlying molecular and cellular mechanisms. This Special Issue is dedicated to bridging this gap ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Short Review of Diffusion Models and their Possibilities to Enhance Imaging Biomarkers for Neurodegenerative Diseases
Current Medical Imaging Update to Medicinal Chemistry of Nicotinamide in the Treatment of Ischemia and Reperfusion
Medicinal Chemistry Reviews - Online (Discontinued) The Concept of “Neuroprotection” in Neurological Diseases
Current Neuropharmacology NGAL is a Precocious Marker of Therapeutic Response
Current Pharmaceutical Design Oligonucleotide-Based Molecular Therapy for Restenosis after Angioplasty
Current Drug Targets Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Nitric Oxide in Cardiac Transplantation
Vascular Disease Prevention (Discontinued) Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy
Current Pharmaceutical Design Prevention of Cell Damage in Ischaemic-Reperfusion: Mitochondrial Respiratory Chain as a Pharmacological Target
Letters in Drug Design & Discovery Editorial [ Pharmacological Modulation of Liver Ischemia - Reperfusion Injury Executive Editors: G.K. Glantzounis, D.P. Mikhailidis, A.M. Seifalian and B.R. Davidson ]
Current Pharmaceutical Design Novel Strategies for the Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Central Insulin and Insulin-Like Growth Factor-1 Signaling - Implications for Diabetes Associated Dementia
Current Diabetes Reviews Recent Applications of Peanut Phytoalexins
Recent Patents on Food, Nutrition & Agriculture Effectors of Fatty Acid Oxidation Reduction: Promising New Anti-Ischaemic Agents
Current Pharmaceutical Design Curcumin Efficacy in a Serum/Glucose Deprivation-Induced Neuronal PC12 Injury Model
Current Molecular Pharmacology Editorial on the Occasion of the 20th Anniversary of Endocrine Metabolic Immune Disorders-Drug Targets Journal with a Kaleidoscopic Vision of Selected Publications
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting Leukostasis for the Treatment of Early Diabetic Retinopathy
Cardiovascular & Hematological Disorders-Drug Targets Forms of Iron Binding in the Cells and the Chemical Features of Chelation Therapy
Mini-Reviews in Medicinal Chemistry Adenosine, Ketogenic Diet and Epilepsy: The Emerging Therapeutic Relationship Between Metabolism and Brain Activity
Current Neuropharmacology Treatment and Outcome of Pulmonary Arterial Hypertension in HIVInfected Patients: A Review of the Literature
Current HIV Research